叶娜

叶娜.JPG

姓名:叶娜

职务职称:博士,特聘副教授,硕士生导师

联系电话:0512-65881161

联系邮箱:yena@suda.edu.cn

联系地址:苏州市工业园区仁爱路199号药学院云轩楼1225

 

个人简介:

 

一、    学习与工作经历

2016.9–至今:苏州大学,药学院,特聘副教授

2013.6–2016.8:美国德州大学医学分部,博士后

2008.09-2013.06中国科学院上海药物研究所,药物化学,理学博士

2004.09-2008.07沈阳药科大学,国家基础药学理科基地班,理学学士

 

二、    研究方向

1)靶向神经精神性重大疾病的药物研发

2)抗肿瘤药物的设计与合成

3) 有机方法学在药物研发中的应用

 

 

三、    主要学术科研成果 

   

目前主持国家自然科学基金青年项目(81703330)和江苏省自然科学基金项目(BK20170347)1项,还曾参与美国NIHCPRIT等项目研究,至今发表SCI论文30余篇,其中第一作者12篇。参与申报国际发明专利2中国发明专利5项,其中1项中国专利已授权。并编写专著《新药研发案例研究:明星药物如何从实验室走向市场》第十章-氟西汀。2011年,获得“全国药物化学学术会议优秀墙报奖”;2013年,获得中国科学院院长奖学金优秀奖中国科学院优秀毕业生等奖励;另外,设计开发的靶向聚腺苷二磷酸核糖聚合酶PARP抑制剂SOMCL-9112作为抗肿瘤候选药物,已申报化学药品1.1类新药希明哌瑞及其片剂,经CFDA快速审批,已获得临床实验批件,目前正在临床I期研究中(NCT02993913)。

 

代表性论文如下:

1)        Yuan, B.; Ye, N.;# Song, S. S.; Wang, Y. T.; Song, Z.; Chen, H. D.; Chen, C. H.; Huan, X. J.; Wang, Y. Q.; Su, Y.; Shen, Y. Y.; Sun, Y. M.; Yang, X. Y.; Chen, Y.; Guo, S. Y.; Gan, Y.; Gao, Z. W.; Chen, X. Y.; Ding, J.; He, J. X.; Zhang, A.; Miao, Z. H. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer lett., 2017, 386, 47-56. (# 并列第一作者)

2)        Ye, N.; Zhu, Y.; Liu, Z.; Mei, F. C.; Chen, H.; Wang, P.; Cheng, X.; Zhou, J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists. Eur. J. Med. Chem. 2017, 134, 62-71.

3)        Ye, N.; Shi, P.-Y.; Zhou, J. Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis., 2016, 2, 382-292.

4)        Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem.,2015, 58, 6033-6047.

5)        Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem., 2014, 57, 6930-6948.

6)        Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem., 2014, 21, 437-457.

7)        Ye, N.; Zhou, J. KRAS - An Evolving Cancer Target. Austin J. Cancer Clin. Res., 2014, 1, 1004.

8)        Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev., 2013, 113, PR123-178.

9)        Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem., 2013, 56, 2885-2903.

10)    Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the Oxidation of Aryl Oxiranylmethanols and the Synthesis of 2-Aryl-N-thiazolyl-oxirane-2-carboxamides as Glucokinase Activators. Tetrahedron Lett., 2012, 53, 4738–4742.

11)        Zhang, H.; Ye, N.; # Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem., 2011, 54, 4324–4338. (# 并列第一作者)

12)        Ye, N.; Wu, Q.; Zhu, L.; Zheng, L.; Gao, B.; Zhen, X.; Zhang, A. Further SAR Study on 11-O-substituted Aporphine Analogues: Identification of Highly Potent Dopamine D3 Receptor Ligands. Bioorg. Med. Chem., 2011, 19, 1999–2008.